Clinical and echocardiographic characteristics after six months of sacubitril/valsartan in Chagas heart disease - A case series.
Clara Salles FigueiredoRodrigo Morel Vieira de MeloTaina Teixeira VianaAline Grimaldi Queiroz de JesusTainara Cerqueira da SilvaVitor Mamedio da SilvaWilliam Neves de CarvalhoDaniela Nascimento Valame da SilvaLuiz Carlos Santana PassosPublished in: British journal of clinical pharmacology (2021)
Chagas cardiomyopathy is the most prevalent non-ischaemic cardiomyopathy in Latin America, with high morbidity and mortality even today. Treatment of these patients is based on the use of medications for heart failure. This study evaluated a case series of patients with Chagas heart disease who used sacubitril/valsartan at a referral hospital for this disease in Brazil. After 6 months, there was a symptomatic improvement in these individuals assessed by the New York Heart Association (NYHA) functional class, with a 44.3% reduction in the absolute number of patients classified as III-IV in the period (P = 0.035), but without changes in the parameters on the echocardiogram for reverse ventricular remodelling. There was a high mortality rate and number of hospitalizations. These results emphasize the importance of studying the use of sacubitril/valsartan in Chagas heart disease to better describe its effectiveness considering the particularities of these individuals.
Keyphrases
- ejection fraction
- heart failure
- end stage renal disease
- pulmonary hypertension
- newly diagnosed
- chronic kidney disease
- prognostic factors
- left ventricular
- trypanosoma cruzi
- emergency department
- randomized controlled trial
- systematic review
- primary care
- type diabetes
- risk factors
- mitral valve
- left atrial
- acute heart failure
- combination therapy
- drug induced
- cardiac resynchronization therapy